| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-09-06 | Allogene Therapeutics (USA - CA) | $120 Million | financing round | Cancer - Oncology | Financing round | |
| 2018-09-05 | Retrophin (USA - CA) | $240 million | private placement | Rare diseases | Private placement | |
| 2018-08-31 | Antabio (France) | € 12.5 million | series A financing round | iXO Private Equity (France) IRDI SORIDEC Gestion (France) Galia Gestion (France) Omnes Capital (France) BNP Paribas Développement (France) Sham Innovation Santé (Turenne Capital) (France) and company’s historical investors including former President of OM Pharma Christophe Ricard. | Rare diseases - Infectious diseases | Series A financing round |
| 2018-08-16 | Krystal Biotech (USA - PA) | $10 million | private placement | Frazier Healthcare Partners (USA - WA) | Rare diseases - Genetic diseases | Private placement |
| 2018-08-13 | Orchard Therapeutics (UK) | $150 Million | series C financing round | ArrowMark Partners (USA - CO) Cormorant Asset Management (USA - MA) Foresite Capital (USA - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) Venrock (USA - CA) Foresite Capital (USA - NY) Sphera Global Healthcare (Spain) Medison Ventures Driehaus Capital Management (USA - IL) Ghost Tree Capital Group (USA - NY) Temasek (Singpore) Baillie Gifford (UK) Cowen Healthcare (USA - NY) Agent Capital (USA - MA) | Rare diseases - Genetic diseases | Series C financing round |
| 2018-08-08 | Beigene (China) | $903 million | IPO | Cancer - Oncology | IPO | |
| 2018-08-06 | Pharmaxis (Australia) | A$24 million (£13.4 million - €15.35 million) | financing round | Arix Bioscience (UK) BVF Partners (USA - CA) other existing shareholders | Fibrotic diseases - Inflammatory diseases | Financing round |
| 2018-08-03 | Drug Discovery Gateway Investment Limited Partnership - DDG Fund (Japan) | financing round | Takeda Pharmaceutical (Japan) Whiz Partners (Japan) | Financing round | ||
| 2018-07-31 | AC Immune (Switzerland) | $117.5 million | private placement | Neurological diseases - CNS diseases | Private placement | |
| 2018-07-28 | Bluebird Bio (USA - MA) | $550 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2018-07-23 | Azafaros (The Netherlands) | seed financing round | BioGeneration Ventures (The Netherlands) | Rare diseases - Genetic diseases - Metabolic diseases | Financing round | |
| 2018-07-23 | OliX Pharmaceuticals (South Korea) | KRW43 billion ($38 million) | IPO | Fibrotic diseases - Ophtalmological diseases | IPO | |
| 2018-07-06 | Oncologie (USA - MA - China) | $16.5 million | seed financing round | Nan Fung Life Sciences (China) Pivotal bioVenture Partners China Fund (China) China Merchant Bank Investments (China) Volcanics Ventures (China) | Cancer - Oncology | Financing round |
| 2018-06-28 | Innovation Pharmaceuticals (USA - MA) | $7 million | private placement | Aspire Capital (USA - IL) | Cancer - Oncology - Infectious diseases | Private placement |
| 2018-06-25 | Avrobio (USA - MA) | $114.7 million | IPO | Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases | IPO | |
| 2018-06-25 | Akero Therapeutics (USA - MA) | $65 Million | series A financing round | Apple Tree Partners (USA - NY) Atlas Venture (USA - MA) venBio Partners (USA - CA) Versant Ventures (USA - CA) | Liver diseases - Hepatic diseases | Series A financing round |
| 2018-06-12 | MeiraGTx (USA - NY) | $75 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2018-05-30 | Iontas (UK) | £556 000 ($737 000) | grant | Innovate UK (UK) | CNS diseases | Grant |
| 2018-05-29 | Melinta Therapeutics (USA - CT) | private placement | Infectious diseases | Private placement | ||
| 2018-05-29 | Mereo BioPharma (UK) | private placement | Rare diseases | Private placement |
